Syneos Health has entered a strategic partnership with KX, maker of kdb, a time series database and analytics engine. The partnership aims to deliver data-driven predictive analytics, Artificial Intelligence (AI) and Machine Learning (ML) capabilities to help customers address complex clinical development via Data Timehouse, a new class of data and AI management engine designed for temporal data generated by digital transformation.

The alliance aims to provide real-time engagement and faster and more accurate decision-making related to drug trial site selection. Through the collaboration, Syneos Health and KX will work to improve clinical trial efficiency, reduce costs, and speed time to market for therapies.
 
“Our KX partnership advances our ability to deliver data-driven insights and AI-enabled solutions, helping biopharma customers solve their most complex clinical development and commercialization challenges,” said Baba Shetty, President, Technology and Data Solutions, Syneos Health. “We’ve seen first-hand with multiple customers the ability of KX to dramatically accelerate the most challenging computational challenges with massive data sets, supporting use cases including patient simulations (QSP) for clinical and omnichannel/Real World Evidence for commercial.”
 
“Our work with Syneos Health is a game-changer for the industry. Together, we’re unblocking data access and computing challenges, compressing both the timeframes and costs associated with delivering answers to some of the world’s most important and demanding healthcare questions,” said Ashok Reddy, CEO at KX. “Delivering up to one hundred times faster performance at one-tenth the cost of alternative solutions, our Data Timehouse leverages the power of data analytics and AI to enable faster execution of clinical trials and discovery of new drug treatments, ultimately increasing the likelihood of any given trial’s success. We’re proud to partner with Syneos Health on this revolutionary journey.”